Medesis Pharma S.A. (ALMDP.PA) Comparison with companies in other sectors?

Medesis Pharma S.A. has a share price of 5.15M. You can analyze Medesis Pharma S.A. (ALMDP.PA) competitors across different market sectors through stock heatmaps.

What are ALMDP.PA's NET and operating margins?

Medesis Pharma S.A. (ALMDP.PA) operating margin is around -47.60, and net profit margin is approximately -41.40 as of the latest reports.

In what way does ALMDP.PA's earnings per share (EPS) trend reflect its financial momentum?

Medesis Pharma S.A. (ALMDP.PA) EPS is -0.59 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Medesis Pharma S.A. is -0.59, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Medesis Pharma S.A.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Medesis Pharma S.A. like P/E which is -0.92, P/B which is -0.35, and PEG which is -0.06. Compare them with sector averages to evaluate if the stock is priced fairly.

Medesis Pharma S.A.

ALMDP.PA•EURONEXT

Healthcare

Biotechnology

€0.35

€0.00(0.00%)

Fundamental Analysis of Medesis Pharma S.A. (ALMDP.PA)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-0.59

P/E Ratio

-0.59

ROE

0.40%

Net Margin

-41.40%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$1.80M

Shares OutstandingTotal number of shares issued

$5.15M

Book Value/ShareNet worth per share

$-0.99

Revenue/ShareAnnual revenue per share

$0.009

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.59

Net MarginNet income as percentage of revenue

-4140.31%

Operating MarginOperating income as percentage of revenue

-4759.96%

ROEReturn on shareholders' equity

40.07%

ROAReturn on total assets

-93.19%

ROCEReturn on capital employed

132.31%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

Cash/ShareCash and equivalents per share

$0.005

FCF YieldFree cash flow as percentage of market cap

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for ALMDP.PAFinancial Ratios Analysis details for ALMDP.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for ALMDP.PASector Benchmarking details for ALMDP.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Medesis Pharma S.A. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Medesis Pharma S.A.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Medesis Pharma S.A.'s unique business strengths and challenges.

Key Financial Metrics for Medesis Pharma S.A.

For Medesis Pharma S.A., essential financial indicators include EPS -0.59, PE -0.59, and ROE 0.40. These key ratios reveal insights into Medesis Pharma S.A.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Medesis Pharma S.A. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Medesis Pharma S.A.

Metrics like Net Margin -4140.31% and ROA -93.19% shed light on how well Medesis Pharma S.A. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Medesis Pharma S.A. can sustain its operations and continue growing in the future.

Valuation and Market Position of Medesis Pharma S.A.

Using ratios such as P/B Ratio -0.35 and PEG Ratio -0.06, investors can assess whether Medesis Pharma S.A. is appropriately valued based on its financials and growth potential. These figures, combined with Medesis Pharma S.A.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Medesis Pharma S.A.

Financial health indicators, such as Debt/Equity Ratio -0.65 and Cash Flow -, provide a snapshot of Medesis Pharma S.A.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Medesis Pharma S.A., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Medesis Pharma S.A.

Investing in Medesis Pharma S.A. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Medesis Pharma S.A. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;